TrialBlood2019

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.

Meletios Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.